EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Sintilimab and Cardiovascular Toxicity—Reply

Jianming Xu, ORIENT-16 Investigators

JAMA · 2024

DOI: 10.1001/jama.2024.0676 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Jianming Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cardiovascular Diseases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCardiovascular DiseasesImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCardiovascular SystemHeartRandomized Controlled Trials as TopicMyocarditisCreatine Kinase, MB FormBiomarkers

Substanzen

Antibodies, Monoclonal, HumanizedsintilimabCreatine Kinase, MB FormBiomarkersImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

Zitieren

APA

Xu, J., & ORIENT-16 Investigators (2024). Sintilimab and Cardiovascular Toxicity—Reply. JAMA. https://doi.org/10.1001/jama.2024.0676

Vancouver

Xu J, ORIENT-16 Investigators. Sintilimab and Cardiovascular Toxicity—Reply. JAMA. 2024. doi:10.1001/jama.2024.0676

BibTeX
@article{Xu2024,
  author = {Xu, Jianming and ORIENT-16 Investigators, ORIENT-16 Investigators},
  title = {Sintilimab and Cardiovascular Toxicity—Reply},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.0676}
}
Kostenlos starten →